As of November 6, 2026, Adverum Biotechnologies, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 8 filings are on record since July 16, 2025 (Schedule 13D/A, December 9, 2025).
Sell to companies like Adverum Biotechnologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Frazier Life Sciences Public Fund, L.P. · Percent: 0% · Shares: 0 · SCHEDULE 13G/A
- · Holder: BML Investment Partners, L.P. · Percent: 0% · Shares: 0 · SCHEDULE 13D/A
- · Holder: BML Investment Partners, L.P. · Percent: 9.7% · SCHEDULE 13D/A
- · Holder: Frazier Life Sciences Public Fund, L.P. · Percent: 19.4% · SCHEDULE 13G/A
- · Holder: BML Investment Partners, L.P. intent stated · Percent: 15.6% · SCHEDULE 13D/A
Adverum Biotechnologies, Inc. has 8 Schedule 13D or 13G filings on record since 2025-07-16. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 BML Investment Partners, L.P.
On November 10, 2025, the Reporting Persons sent a letter to the Board of the Issuer detailing the Reporting persons dissapointment with the current deal with Lilly and the lack of a full sale process.From Item 4 of the SCHEDULE 13D/A filed 2025-11-10
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 2% | 414,485 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Franklin Resources, Inc. | 0% | 0 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-12-09 | 2025-12-09 |
| BML Investment Partners, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-12-09 | 2025-12-09 |
Holding shares or following this stake? See who's behind Adverum Biotechnologies, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Adverum Biotechnologies, Inc. and the records around it.
Adverum Biotechnologies, Inc. elsewhere on the record
- Acquisition Dec 2025
Companies that share a holder
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- Franklin Resources, Inc. also filed stake reports on 41 other companies: Adicet Bio, Inc. (Oct 2026), ALBEMARLE CORPORATION (Oct 2026), Andersen Group Inc. (Oct 2026)
Watch Adverum Biotechnologies, Inc.
Get an email when Adverum Biotechnologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adverum Biotechnologies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Adverum Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adverum Biotechnologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
BML Investment Partners, L.P.
All of the Common Stock of the Issuer reported on this Schedule 13D was acquired in the ordinary course of business by the reporting persons for investment purposes. The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D. The reporting persons may evaluate on a continuing basis the investment in the Issuer and may, from time to time, acquire or dispose of Common Stock of the Issuer. Any such acquisitions or dispositions will depend upon (i) the price and availability of the Issuer's securities; (ii) subsequent developments concerning the Issuer's business and prospects and the industry in which the Issuer operates; (iii) investment policies of the reporting persons; (iv) other investment opportunities available to the reporting persons; (v) general market and economic conditions; (vi) tax considerations; and (viii) such other factors as the reporting persons may deem relevant. Any such acquisitions or dispositions may be made, subject to applicable law, in open market transactions. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage in discussions with the Issuer and its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or discuss with the Issuer different strategic …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2% | SCHEDULE 13G/A |
| 2025-08-05 | Franklin Resources, Inc. | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.4% | SCHEDULE 13G/A |
| 2025-11-10 | BML Investment Partners, L.P. intent stated | 15.6% | SCHEDULE 13D/A |
| 2025-11-28 | Frazier Life Sciences Public Fund, L.P. | 19.4% | SCHEDULE 13G/A |
| 2025-12-05 | BML Investment Partners, L.P. | 9.7% | SCHEDULE 13D/A |
| 2025-12-09 | Frazier Life Sciences Public Fund, L.P. | 0% | SCHEDULE 13G/A |
| 2025-12-09 | BML Investment Partners, L.P. | 0% | SCHEDULE 13D/A |
Also on the record for Adverum Biotechnologies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 7, 2025 | Acquired by Eli Lilly and Company | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Adverum Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.